Author:Ismail, Sherazaan DineoDate:2016The CAPRISA 004 trial demonstrated the safety and a 39% efficacy of a 1% tenofovir (TFV) gel for the prevention of HIV-1 acquisition in young African women. It was subsequently shown that women assigned to the TFV arm who became infected had ...Read more
Author:Kariuki, Samuel Mundia; Selhorst, Philippe; Ariën, Kevin K; Dorfman, Jeffrey RobertDate:25 Mar 2017It is well established that most new systemic infections of HIV-1 can be traced back to one or a limited number of founder viruses. Usually, these founders are more closely related to minor HIV-1 populations in the blood of the presumed donor ...Read morecb
Author:Kariuki, Samuel M; Selhorst, Philippe; Ariën, Kevin K; Dorfman, Jeffrey RDate:23 Mar 2017It is well established that most new systemic infections of HIV-1 can be traced back to one or a limited number of founder viruses. Usually, these founders are more closely related to minor HIV-1 populations in the blood of the presumed donor ...Read more